Advances in Neurologic Devices*
Date/Time: Sunday, September 10, 2023 - 11:45 AM – 12:45 PM
Track: Interactive Lunch Workshop
Room: Salons C-D (5th Floor)
Log in to Add to My Schedule
Description:
Session Evaluation Form: https://myana.org/form/ana2023-session-evaluationadvan
Chair: Richa Tripathi, MD
Co-Chair: Eric Wong, MD, FANA, FAAN
Over the last decade there has been a dramatic change in the management of several neurological disorders. One of the biggest components is the use of devices that rely on the principles of neuromodulation to treat disorders. Not all hospitals or academic centers in the country have access to the same. There is lack of knowledge about the applicability and use of such treatment options amidst neurologists that may not have directly dealt with these devices. This session aims to communicate the latest scientific data and clinical application of neurologic devices. This topic is important and timely due to the proliferation of FDA-approved devices for numerous neurologic disorders. Even though this session does not aim to train the audience in using such devices, our hope is that the audience understands the basic principles of action as well as clinical utility of such devices. This would facilitate appropriate referral to institutes that can provide required care for the patient. Such devices have not only shown significant long-term impact in fact early intervention has been encouraged for overall improved quality of life. At times therapy devices may allow use of less toxic non-invasive interventions such as use of treating tumor fields in glioblastoma. We will cover deep brain stimulation in movement disorder, spinal cord stimulation as well as tumor treating device in neuro-oncology this year.
Learning Objectives:
- Deep Brain Stimulation in various movement disorders: Potential risks and benefits of the procedures. Potential candidates for procedures. Available technology that aids DBS programming. Future directions of DBS.
- Spinal cord stimulators for pain: Potential risks and benefits of the procedures. Potential candidates for procedures. Available technology that aids Spinal cord stimulation including patient remote control.
- Tumor treating fields therapy: Potential risks and benefits of the procedures. Potential candidates for procedures. Management of medication and device therapy in glioblastoma. Future directions of tumor treating fields therapy.
Spinal Cord Stimulation – Therapy and Advances
Speaker: Peter Konrad, MD, PhD
Neuromodulation began as therapy for pain and spinal cord stimulation was one of it initial success stories. However, the past 10 years of research has revealed many more opportunities for spinal cord stimulation to provide not only effective pain relief but also relief for autonomic disorders, rehabilitation, and sensory restoration in patients with significant brain and spinal cord disease. This presentation will briefly review the existing FDA indications for current spinal cord stimulation devices as well as provide literature evidence of newer potential therapies on the near horizon.
Deep Brain Stimulation in Movement Disorders - Therapy and Advances
Speaker: Christine Esper, MD
This talk will give an overview of deep brain stimulation therapy in movement disorders, including indications, applications, as well as a description of the various programming platforms available today.
Neurologic Device for Glioblastoma and Scientific Basis of Tumor Treating Fields
Speaker: Eric Wong, MD, FANA, FAAN
The Tumor Treating Fields device (NovoTTF-100A or NovoTTF-200A) non-invasively delivers alternating electric fields at 200 kHz to treat glioblastoma. The fields are delivered by transducer arrays applied to the scalp of patients. They are known to disrupt tumor cell mitosis and trigger effectors from both innate and adaptive immune systems to carry out anti-tumor immunity. Clinical efficacy against newly diagnosed glioblastomas has been demonstrated in a randomized phase 3 clinical trial when the device was applied together with chemotherapy after radiation, and this led the FDA approve its use in 2015. Other registration trials in non-small cell lung cancer, pancreatic cancer, and ovarian cancer are currently underway.